Using genetic testing to improve cancer care for children

Genetic testing to guide pediatric cancer care and follow up: using anthracycline-associated cardiac toxicity as a model for the future

NIH-funded research Boston Children's Hospital · NIH-10476300

This study is looking at how genetic testing can help doctors understand the risk of heart problems in kids who have had cancer treatment with certain chemotherapy drugs, so they can create safer and more personalized treatment plans for them.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBoston Children's Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-10476300 on NIH RePORTER

What this research studies

This research investigates how genetic testing can help predict the risk of heart problems in children who have been treated for cancer, specifically those who received anthracycline chemotherapy. By identifying genetic markers associated with treatment-related toxicity, the study aims to tailor cancer therapies to minimize long-term health risks while effectively managing the disease. The approach focuses on understanding individual genetic profiles to adapt treatment plans and follow-up care, ultimately enhancing patient outcomes. The research also addresses the challenges of studying rare childhood cancers and the long-term effects of treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research include children who have been treated for cancer with anthracycline chemotherapy and may have a genetic predisposition to cardiac toxicity.

Not a fit: Patients who have not undergone anthracycline treatment or those with cancers that do not involve this type of chemotherapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to personalized cancer treatments that reduce the risk of serious heart complications in childhood cancer survivors.

How similar studies have performed: Previous research has shown promise in using genetic markers to guide treatment decisions in cancer care, indicating that this approach could be effective.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancersneoplasm/cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.